Release in Europe and Launch in India, Plus Cultivation of New Clients in Asia
28 June 2012
Automatic Blood Cell Counter and CRP Analyzer: Release in Europe and Launch in India, Plus Cultivation of New Clients in Asia
Next month, Horiba will begin sales of its flagship medical product, the Automatic Blood Cell Counter and CRP Analyzer, in Europe, and make a full-scale market entry in India with this product. The top-of-the-line model of our compact diagnostic instruments, this is the only device in the world that can offer complete blood cell count (CBC) and CRP quantitative analysis simultaneously through patented technology.
India's economy is growing at an incredible pace and Horiba is preparing to expand sales in this promising market by cultivating new customers such as small-scale hospitals. Horiba plans to release the Automatic Blood Cell Counter and CRP Analyzer in Korea, Thailand and other Asian countries, as well as in the Americas. Our goal is to sell a total of 3,000 units in overseas markets in the next five years.
Horiba's international deployment strategy for the compact Automatic Blood Cell Counter and CRP Analyzer
Horiba ABX SAS, our subsidiary in France, possesses an extensive international sales and service network. Using this network, we have offered our automatic blood cell counters and reagents to hospitals, satellite laboratories, health care clinics, and private practitioners.
We developed and produced the Automatic Blood Cell Counter and CRP Analyzer as a top-of-the-line device to provide diagnostic results rapidly from miniscule blood samples, and we plan to release the product in Europe as part of an effort to improve our competitiveness in existing markets. At the same time, we will also make a full-scale business launch in India, a country experiencing high economic growth and expansion of its health care industry. We will begin by reinforcing service and sales personnel at local corporations for the purpose of strengthening marketing functions and organizing a basic sales structure. We will release the product by the end of the year in an attempt to cultivate new customers. We also plan to market the product in Korea, Thailand and other Asian countries, as well as in the North and South Americas.
300 units for the first year / total of 3,000 units in five years
19 items (18 completer blood cell count (CBC) including three-part WBC differential , and CRP quantitative analysis)
240 sec. (65 sec. for CBC only)